<DOC>
	<DOCNO>NCT01685489</DOCNO>
	<brief_summary>This phase 1b study follow 3+3 dose escalation design consist 21-day lead-in period oral Polysaccharide Krestin ( PSK ) /placebo ( study drug ) alone follow addition study drug standard intravenous docetaxel 75 mg/m2 every 3 week three cycle . Study drug discontinue day 15 third docetaxel cycle allow 7-day washout period fourth dose docetaxel . Pharmacokinetic ( PK ) analysis docetaxel conduct docetaxel cycle 1 ( combination therapy ) cycle 4 ( docetaxel alone ) . Serum future PSK PK analysis collect day 1 , 3 , 15 PSK/placebo lead-in cycle 1 4 .</brief_summary>
	<brief_title>A Phase 1b Dose Escalation Trial PSK®/Placebo With Docetaxel Treat Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Male patient 18 year old Histologically confirm diagnosis adenocarcinoma prostate Evidence metastatic disease standard image study ( bone scan , Computerized Tomography Scan ( CT ) Magnetic Resonance Imaging ( MRI ) ) Testosterone level &lt; 50 ng/dL Confirmed progressive disease define one following : increase PSA , &gt; 2ng/dL x 2 value least 1 week apart set metastatic disease appearance new bone lesion bone scan progression soft tissue lesion define Response Evaluation Criteria In Solid Tumors [ RECIST ] 1.1 criterion Concurrent use agent testosterone suppression ( e.g. , Luteinizing Hormone Releasing Hormone [ LHRH ] agonist ) patient surgically castrate Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 determine within 28 day enrollment Recovery CTCAE grade ≤ 1 toxicity , patient 's baseline status ( except alopecia ) , toxicity deem irreversible effect prior cancer therapy ( CTCAEs grade &gt; 1 consider safety risk investigator allow ) Adequate bone marrow function define : absolute neutrophil count ( ANC ) &gt; 1500 cells/mm³ without growth factor support platelet count &gt; 100,000 cells/mm³ without transfusion growth factor support hemoglobin &gt; 9g/dL without transfusion growth factor support Adequate liver function define : total bilirubin &lt; upper limit normal ( ULN ) alanine aminotransferase ( ALT ) &lt; 1.5 x ULN aspartate aminotransferase ( AST ) &lt; 1.5 x ULN Adequate renal function define serum creatinine level within normal limit ( WNL ) At least 6month great life expectancy Ability understand sign write informed consent , obtain study participant undergo studyspecific procedure Willing able comply schedule visit , treatment plan , laboratory test , trial procedure Suitable venous access studyrequired blood sampling ( i.e. , include PK sampling ) Prior treatment antineoplastic chemotherapy radioisotopes metastatic disease Prior adjuvant neoadjuvant chemotherapy within 12 month study entry Last dose sipuleucelT therapy within 4 week enrollment Any investigational therapy within 4 week study entry Radiotherapy within 4 week study entry Major surgery within 4 week study entry , fully recover baseline stable clinical status Uncontrolled high blood pressure ( systolic blood pressure &gt; 160mmHg , diastolic blood pressure &gt; 95mmHg ) Receiving chronic steroid therapy . Topical inhale steroid permit Known severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 , mushroom product Any comorbid condition unresolved toxicity would preclude administration docetaxel Medical contraindication docetaxel premedications History &gt; grade 2 neurotoxicity toxicity cause resolve &lt; grade 1 Brain CNS metastasis The need chronic daily immunosuppressive therapy , include concurrent use prednisone Evidence active second malignancy , except nonmelanoma skin cancer Infection require intravenous antibiotic therapy severe infection within 14 day precede first dose study drug Inability swallow oral medication maintain fast , require 2 hour 1 hour PSK administration Uncontrolled pain baseline , impend complication bone metastasis and/or presence urinary obstruction Other medical psychiatric condition may increase risk associate trial participation condition judgment investigator may interfere interpretation trial result would make patient inappropriate enrollment trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castrate resistant</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>PSK</keyword>
	<keyword>Krestin</keyword>
	<keyword>Trametes versicolor</keyword>
	<keyword>Safety</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Mushroom</keyword>
	<keyword>Natural</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>